-$0.41 EPS Expected for Intersect ENT Inc (NASDAQ:XENT) This Quarter

Analysts expect Intersect ENT Inc (NASDAQ:XENT) to announce earnings of ($0.41) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Intersect ENT’s earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.46). Intersect ENT posted earnings per share of ($0.25) in the same quarter last year, which indicates a negative year over year growth rate of 64%. The company is expected to announce its next earnings results on Monday, November 4th.

On average, analysts expect that Intersect ENT will report full year earnings of ($1.42) per share for the current year, with EPS estimates ranging from ($1.50) to ($1.30). For the next financial year, analysts forecast that the business will post earnings of ($1.28) per share, with EPS estimates ranging from ($1.43) to ($1.10). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Intersect ENT.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.02). The business had revenue of $26.66 million for the quarter, compared to analyst estimates of $27.13 million. Intersect ENT had a negative return on equity of 29.16% and a negative net margin of 31.43%. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.14) EPS.



A number of equities research analysts have recently commented on XENT shares. Piper Jaffray Companies lowered Intersect ENT from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $30.00 to $17.00 in a research report on Friday, August 2nd. Berenberg Bank downgraded Intersect ENT from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $35.00 to $27.00 in a report on Friday, June 21st. Zacks Investment Research downgraded Intersect ENT from a “hold” rating to a “strong sell” rating in a report on Friday, May 3rd. Leerink Swann downgraded Intersect ENT from an “outperform” rating to a “market perform” rating and set a $25.75 price objective for the company. in a report on Tuesday, May 7th. Finally, Guggenheim downgraded Intersect ENT from a “buy” rating to a “neutral” rating in a report on Friday, August 2nd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $27.11.

Shares of NASDAQ XENT traded up $0.46 during mid-day trading on Friday, reaching $16.43. 7,896 shares of the company’s stock were exchanged, compared to its average volume of 518,695. The firm has a market capitalization of $525.59 million, a price-to-earnings ratio of -21.66 and a beta of 0.79. The business has a fifty day simple moving average of $19.67 and a 200 day simple moving average of $26.82. Intersect ENT has a twelve month low of $15.76 and a twelve month high of $35.87.

Several large investors have recently bought and sold shares of XENT. Quantamental Technologies LLC grew its holdings in shares of Intersect ENT by 211.0% during the first quarter. Quantamental Technologies LLC now owns 1,950 shares of the medical equipment provider’s stock worth $63,000 after buying an additional 1,323 shares in the last quarter. Legal & General Group Plc grew its stake in Intersect ENT by 14.8% in the fourth quarter. Legal & General Group Plc now owns 5,353 shares of the medical equipment provider’s stock valued at $151,000 after purchasing an additional 690 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in Intersect ENT by 62,220.0% in the first quarter. BNP Paribas Arbitrage SA now owns 6,232 shares of the medical equipment provider’s stock valued at $200,000 after purchasing an additional 6,222 shares in the last quarter. NumerixS Investment Technologies Inc grew its stake in Intersect ENT by 190.9% in the first quarter. NumerixS Investment Technologies Inc now owns 6,400 shares of the medical equipment provider’s stock valued at $200,000 after purchasing an additional 4,200 shares in the last quarter. Finally, Meeder Asset Management Inc. grew its stake in Intersect ENT by 15.0% in the first quarter. Meeder Asset Management Inc. now owns 6,443 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 839 shares in the last quarter. Institutional investors and hedge funds own 92.42% of the company’s stock.

About Intersect ENT

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Recommended Story: Do equity income investments outperform growth and income investments?

Get a free copy of the Zacks research report on Intersect ENT (XENT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.